Diabetic retinopathy, characterized as a microangiopathy and neurodegenerative disease,
is the leading cause of visual impairment in diabetic patients. Many clinical features …

Purpose To review the current therapeutic options for the management of diabetic
retinopathy (DR) and diabetic macular edema (DME) and examine the evidence for …

Background: Diabetic retinopathy is a leading cause of visual impairment in working-age
adults worldwide. Duration of diabetes is a major risk factor associated with the development …

Diabetic macular edema (DME) is the most common cause of vision loss in patients with
diabetic retinopathy with an increasing prevalence tied to the global epidemic in type 2 …

Purpose To evaluate the safety and efficacy of dexamethasone intravitreal implant (Ozurdex,
DEX implant) 0.7 and 0.35 mg in the treatment of patients with diabetic macular edema …

Diabetes mellitus (DM) is a important health problem that induces ernestful complications
and it causes significant morbidity owing to specific microvascular complications such as …

Diabetes causes a number of metabolic and physiologic abnormalities in the retina, but
which of these abnormalities contribute to recognized features of diabetic retinopathy (DR) is …

OBJECTIVE: Evaluate intravitreal 0.5 mg ranibizumab or 4 mg triamcinolone combined with
focal/grid laser compared with focal/grid laser alone for treatment of diabetic macular edema …

Introduction: Diabetic retinopathy (DR) is the leading cause of vision loss in the working age
population of the developed world. DR encompasses a complex pathology, and one that is …

The management of diabetic retinopathy (DR) has evolved considerably over the past
decade, with the availability of new technologies (diagnostic and therapeutic). As such, the …